Assessment of the implementation of safe medication practices in Intensive Medicine Units.

OBJECTIVE: To assess the level of implementation of medication safety practices in Intensive Care Units (ICUs) and to identify opportunities for improvement. DESIGN: A descriptive multicenter study was carried out. SETTING: Intensive Care Units. PARTICIPANTS/PROCEDURE: A total of 40 ICUs voluntarily completed the "Medication use-system safety self-assessment for Intensive Care Units" between March and September 2020. The survey comprised 147 items for evaluation grouped into 10 key elements. MAIN VARIABLES: Calculation was made of the mean scores and mean percentages based on the maximum possible values for the overall survey, referred to the key elements and to each individual item for evaluation. RESULTS: The mean score of the overall questionnaire among the participating ICUs was 436.8 (49.2% of the maximum possible score). No differences were found according to functional dependence, size of the hospital or type of ICU. The key elements referred to the incorporation of clinical pharmacists in these Units, as well as the competence and training of the professionals in safety practices yielded the lowest values (31.2% and 33.2%, respectively). Three other key elements related to accessibility to information about patients and medicines; to the standardization, storage and distribution of medicines; and to the quality and risk management programs, yielded percentages <50%. CONCLUSIONS: Numerous effective safety medication practices have been identified with a low level of implementation in ICUs. This situation must be addressed in order to reduce medication errors in critically ill patients.

Assessment of the implementation of safe medication practices in Intensive Medicine Units. / Evaluación de la implantación de prácticas seguras con los medicamentos en los Servicios de Medicina Intensiva.

OBJECTIVE: To assess the level of implementation of medication safety practices in Intensive Care Units (ICUs) and to identify opportunities for improvement. DESIGN: A descriptive multicenter study was carried out. SETTING: Intensive Care Units. PARTICIPANTS/PROCEDURE: A total of 40 ICUs voluntarily completed the "Medication use-system safety self-assessment for Intensive Care Units" between March and September 2020. The survey comprised 147 items for evaluation grouped into 10 key elements. MAIN VARIABLES: Calculation was made of the mean scores and mean percentages based on the maximum possible values for the overall survey, for the key elements and for each individual item for evaluation. RESULTS: The mean score of the overall questionnaire among the participating ICUs was 436.8 (49.2% of the maximum possible score). No differences were found according to functional dependence, size of the hospital or type of ICU. The key elements referred to the incorporation of clinical pharmacists in these units, as well as the competence and training of the professionals in safety practices yielded the lowest values (31.2% and 33.2%, respectively). Three other key elements related to accessibility to information about patients and medicines; to the standardization, storage and distribution of medicines; and to the quality and risk management programs, yielded percentages below 50%. CONCLUSIONS: Numerous effective safety medication practices have been identified with a low level of implementation in ICUs. This situation must be addressed in order to reduce medication errors in critically ill patients.

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation.

BACKGROUND: Cancer is the second leading cause of mortality worldwide. Integrating different levels of care by implementing screening programmes, extending diagnostic tools and applying therapeutic advances may increase survival. We implemented a cancer fast-track programme (CFP) to shorten the time between suspected cancer symptoms, diagnosis and therapy initiation. PATIENTS AND METHODS: Descriptive data were collected from the 10 years since the CFP was implemented (2009-2019) at the Clinico-Malvarrosa Health Department in Valencia, Spain. General practitioners (GPs), an oncology coordinator and 11 specialists designed guidelines for GP patient referral to the CFP, including criteria for breast, digestive, gynaecological, lung, urological, dermatological, head and neck, and soft tissue cancers. Patients with enlarged lymph nodes and constitutional symptoms were also considered. On identifying patients with suspected cancer, GPs sent a case proposal to the oncology coordinator. If criteria were met, an appointment was quickly made with the patient. We analysed the timeline of each stage of the process. RESULTS: A total of 4493 suspected cancer cases were submitted to the CFP, of whom 4019 were seen by the corresponding specialist. Cancer was confirmed in 1098 (27.3%) patients: breast cancer in 33%, urological cancers in 22%, gastrointestinal cancer in 19% and lung cancer in 15%. The median time from submission to cancer testing was 11 days, and diagnosis was reached in a median of 19 days. Treatment was started at a median of 34 days from diagnosis. CONCLUSIONS: The findings of this study show that the interval from GP patient referral to specialist testing, cancer diagnosis and start of therapy can be reduced. Implementation of the CFP enabled most patients to begin curative intended treatment, and required only minimal resources in our setting.

Patch Testing During the COVID-19 Pandemic: Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC). / Recomendaciones del Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC) de la AEDV en relación con la realización de pruebas epicutáneas durante la pandemia por SARS-CoV-2 (COVID-19).

As the COVID-19 pandemic gradually comes under control, the members of the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) have drawn up a proposed list of the requirements, limitations, and conditioning factors affecting the resumption of work in contact dermatitis units. The assumption is that the severe acute respiratory syndrome coronavirus2 is still circulating and that occasional or seasonal outbreaks will occur. They recommend that the first step should be to assess how many patch tests each clinic can handle and review the waiting list to prioritize cases according to disease severity and urgency. Digital technologies can, where possible, be used to send and receive the documentation necessary for the patch test (information, instructions, informed consent, etc.). If the necessary infrastructure is available, patients can be offered the option of a remote initial consultation. Likewise, in selected cases, the patch test results can be read in a virtual visit using photographs taken by the patient or a video visit can be scheduled to allow the physician to evaluate the site of application remotely. These measures will reduce the number of face-to-face visits required, but will not affect the time spent on each case, which must be scheduled in the normal manner. All of these recommendations are suggestions and should be adapted to the needs and possibilities of each health centre.

Assessment of subclinical atherosclerosis in hidradenitis suppurativa.

BACKGROUND: Patients with hidradenitis suppurativa (HS) have an increased prevalence of traditional cardiovascular risk factors. OBJECTIVE: Our aim was to investigate the association between subclinical atherosclerosis, detected by carotid ultrasound, and HS. METHODS: A prospective observation and analytical study assessing subclinical atherosclerosis using carotid ultrasound in patients with HS. RESULTS: A total of 62 HS patients and 62 matched controls were studied. Diabetes mellitus (22.6% vs. 6.5%, P = 0.020), hypertension (41.9% vs. 12.9%, P < 0.001) and metabolic syndrome (MetS) (38.7% vs. 8.1%, P < 0.001) were more common in HS patients. Elevated neutrophil-to-lymphocyte ratio (59.7% vs. 40.3%, P = 0.031), high-sensitivity C-reactive protein (61.1 vs. 29.0%, P < 0.001) and erythrocyte sedimentation rate (46.8% vs. 9.7%, P < 0.001) were more frequent in patients with HS. Subclinical atherosclerosis was present in 30.6% of HS patients and in 16.1% of the controls subjects (P = 0.06). After a logistic regression analysis, elevated age was associated with the presence of subclinical atherosclerosis (P < 0.001), and HS showed a tendency towards this association [adjusted OR (95% CI) 3.8 (0.9-16.0), P = 0.066]. This association was statistically significant between patients 40 years and older [OR (95% CI) 4.9 (1.8-13.1)]. CONCLUSIONS: Our clinical results indicate that patients with HS have a higher prevalence of subclinical atherosclerosis than expected when correcting for traditional risk factors. The findings support the conclusions of previous epidemiological studies.

Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.

PURPOSE: This study aims to asses a cancer fast-track programme (CFP) to shorten the time since a patient with suspicion of cancer is referred by the primary care (PC) physician to the specialized medical team. METHODS: Guidelines for main suspected tumours were designed to help PC physicians to detect and rapidly refer cases to the CFP oncology coordinator, who sent them to the appropriate department to accelerate diagnosis, staging and therapy. All patients analysed in this report were referred from June 2009 to July 2012. RESULTS: A total of 897 suspected cancer cases were submitted and finally 705 were studied. In 205 (29 %) a cancer diagnosis was confirmed within 23 days (median). Therapy was initiated within 46 days after referral (median). Early diagnoses with a potential curative approach were made in 166 (82 %). CONCLUSIONS: This CFP decreased the waiting time for cancer diagnosis, by improving communication between PC physician and specialized care teams. Most patients included in this program could get therapy with curative intent.

Variabilidad interinstitucional del tamiz neonatal en México / Institutional variability of neonatal screening in Mexico

Introducción. Actualmente, los avances tecnológicos han hecho factible el tamiz neonatal (TN) para un número cada vez mayor de enfermedades. En México, la normatividad vigente se ha mantenido sin cambios desde 1988, contemplando únicamente la detección del hipotiroidismo congénito; sin embargo, el TN ha evolucionado de manera diferenciada en el sector salud. Objetivo: conocer la variabilidad del número de enfermedades detectadas mediante el TN y las metodologías utilizadas para su realización en las distintas instituciones del sistema de salud mexicano. Métodos. Se realizaron entrevistas telefónicas con los coordinadores estatales del Programa de TN. Resultados. Algunas instituciones realizan el tamiz para una enfermedad, mientras que otras lo practican hasta para 60 enfermedades. Las metodologías empleadas van de 1 a 5. Conclusión. Existe gran variabilidad en el número de enfermedades que se tamizan, así como en las metodologías empleadas; dicha variabilidad depende del lugar del nacimiento y la adscripción laboral de los padres. La variabilidad conduce a inequidad en la oportunidad de que a los recién nacidos se les detecten enfermedades congénitas graves, que tienen un alto potencial generador de discapacidad, por lo que es importante que se establezcan políticas de salud equitativas, justas y modernas sobre el TN en México.

Introduction. Recently, the development of technology has reached the availability of neonatal screening (NS) for an increasing number of diseases. In Mexico, the actual official regulation makes obligatory the detection of only one disease -hypothyroidism. Despite this, the regulation has remained without changes since 1988. Panels involved in NS have evolved differently in the Mexican health sector. We undertook this study to determine the variability of the NS panels and the number of detected diseases as well as the diverse methodologies used for their determination in the different institutions of the Mexican health system. Methods. Telephone interviews were made to the directors of the NS program for each federal entity and institution. Results. We found that some institutions only screen for one disease, whereas others screen for up to 60 diseases. Methodology variation was 1 to 5. Conclusions. There is great variability in the number of diseases detected in newborns as well as in the methodologies used. Such inconsistency depends on the place of birth and the parents' employment for insurance affiliation. This difference leads to unequal opportunities for the detection of severe inherited diseases with high potential of impaired development. It is important to establish equal, fair and modern health policies in regard to NS in Mexico.

Calidad de vida en pacientes con diabetes mellitus controlados en Hospital Galvarino, Servicio de Salud Araucania Sur / Quality of life of patients with diabetes mellitus controlled at the Galvarino Hospital, Health Service of Araucania South

Diabetes mellitus is a chronic disease with an increasing prevalence and a raised life expectancy of patients.Since it is a disease presenting with multiple complications during its evolution special emphasis should be given to ever greather efforts for improving quality of life of the patients.A sample of 50 persons comprising 50 per cent of the diabetic population controlled by the Cardiovascular Programme of the Galvarino Hospital were studied, including a survey to assess their quality of life. Results showed that 100 per cent of the patients had one associated pathology, high blood pressure being the most frequent; 72 per cent were obese while a high percentage showed a deficient metabolic control. 71 per cent had a poorly compensated diabetes and 85 per cent presented high tensional figures at the time of assessment.A Cause of special concern is that none of the patients had a recent eye examination nor a fundoscopy.The above results show the ineffectiveness of the Cardiovascular Health Programme developed by the municipality of Galvarino as well as the absence of basic tools to carry out a proper assessment of diabetic patients.

[Analysis of the effectiveness and costs of amlodipine on the hospitalizations for cardiovascular events in patients with ischemic cardiopathy]. / Análisis de la eficacia y costes de amlodipino sobre las hospitalizaciones por eventos cardiovasculares en pacientes con cardiopatía isquémica.

OBJECTIVE: Evaluation of the effect of amlodipine on the hospitalizations for cardiovascular events (CVE) and their associated costs in patients with ischemic cardiopathy. METHODS: Data from the multicenter, randomized, double-blind, placebo-controlled PREVENT (Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial) clinical trial were utilized. A tree-type model of decision was used in order to analyze the incremental costs expected from the treatment with amlodipine with regard to placebo. Hospitalization costs were estimated with regard to the DRG weights of the American Medicare adapted for the costs of average stay available in our environment. RESULTS: Amlodipine reduced significantly the incidence of CVE that required hospitalization in contrast to placebo; 0.60 +/- 1.16 versus 0.77 +/- 1.31 (average +/- SD), p < 0.05. The expected direct expenses due to hospitalizations were higher in the placebo group than in the amlodipine group (saving of 205.76 Euro/patient). Total cost for patient in the amlodipine group was 1,723.52 Euro while in the placebo group was 1,929.28 Euro. When the relation cost/price shifted in the sensitivity analysis from 1.20 to 0.66 (cost of every hospitalization ranged between + 20% and -34%), the saving fluctuated from 330.56 Euro to 0. Accordingly, the breakeven point of the cost/price relation it is 0.66, and above this the treatment with amlodipine still generates savings in regard to its cost. CONCLUSIONS: Amlodipine is cost-effective in the treatment of the patients with ischemic cardiopathy, being able to reduce the hospital costs related to ischemic episodes in this type of patients.

[Transbronchial needle aspiration in bronchogenic carcinoma with visible lesions: diagnostic yield and cost]. / Punción transbronquial en el carcinoma broncogénico con lesión visible: rendimiento y coste económico.

BACKGROUND: Transbronchial needle aspiration (TBNA) is a bronchoscopic technique whose usefulness in diagnosing endobronchial lesions has not yet been clearly established. OBJECTIVE: We aimed to determine whether the diagnostic yield of fiberoptic bronchoscopy could be increased, without a negative impact on diagnostic costs, if TBNA were used in combination with conventional diagnostic techniques (bronchial washings and bronchial brushings and forceps biopsy). PATIENTS AND METHODS: The cases of 130 patients diagnosed with bronchogenic carcinoma with endoscopically visible lesions were analyzed retrospectively. All had undergone conventional diagnostic procedures; TBNA was also performed if the bronchoscopist considered it was indicated. The final cost was calculated in euros for each diagnosis as the sum of the cost of the procedures needed to reach the diagnosis, including both endoscopic procedures and others (transthoracic needle aspiration, lymph node biopsy). Diagnostic yield and costs in cases diagnosed using only conventional techniques were compared to the yield and costs in cases in which both conventional techniques and TBNA were used. RESULTS: TBNA was performed in 49 patients and provided the diagnosis in 85.7%. Conventional techniques led to cytological and histological diagnosis in 80.2% of the cases, and the combination of conventional techniques and TBNA gave a diagnosis in 89.7% (P=.01). Significant differences were observed in extrinsic compression (conventional 37.5%; conventional+TBNA 100%; P=.01), submucosal infiltration (conventional 54.6%; conventional+TBNA 85%; P=.03), and exophytic mass with necrosis (conventional 80%; conventional+TBNA 100%; P=.01). The mean (SD) cost of diagnosis was euros 381.60 (euros 156.53) using conventional techniques and euros 413.25 (euros 112.91) for conventional techniques in combination with TBNA. By adding TBNA, costs decreased for diagnoses of submucosal infiltration, exophytic mass with necrosis and extrinsic compression, although the saving was significant only for extrinsic compression. CONCLUSION: The diagnostic yield of TBNA is high for endoscopically visible bronchial anomalies suggesting neoplasm, particularly when the lesion is due to extrinsic compression, submucosal infiltration, or exophytic mass with necrosis.

Estudio de costos del procuramiento renal en Chile / Costs study of the organ procurement in Chile

El objetivo de esta investigación fue conocer cuáles son los costos reales del procuramiento renal nacional. Se efectuó un análisis retrospectivo entre 1996 y 1999 de los costos fijos y costos variables, los que se prorratearon por el número total de riñones procurados, el que fue definido como la unidad. El análisis demuestra que el costo unitario es de 930.000 pesos (U$ 1.735), en el año 1999. El FONASA entrega a la Corporación de Transplante el equivalente a U$ 600. Existen variabilidad anual, en términos de que a mayor cantidad de riñones obtenidos, su costo unitario disminuye por la mayor eficiencia del uso de los costos fijos. En países desarrollados el costo unitario de un rinón procurado fluctúa entre U$ 9.600 y U$ 16.900, con un promedio de U$ 13.417. Existen algunos costos que en nuestro estudio se encuentran subvalorados, dado que algunas de las presentaciones son hechas gratuitamente como acciones de beneficencia. Para que esta actividad permanezca en el tiempo, se requiere de un mayor financiamiento a fin de poder darle proyecciones necesarias para satisfacer la creciente demanda de órganos que existe a nivel nacional

Diagnosis of inborn errors of metabolism.

Systematic detection of inborn errors of metabolism (IEM) has usually encountered difficulties in developing countries. We present our experience in a high-risk population in Mexico between 1973 and 1998 with particular reference to the last 10 years, during which time infrastructure and support were considerably improved. Only disorders of intermediary metabolism were sought. The total number of patients studied is not available, but in the last 10 years, patients numbered 5,186. Routine metabolic screening was performed on all patients, with additional tests according to the clinical picture and screening results. The referral criteria have increasingly diversified, one-third being neurological conditions. Of the referrals, 33.8% were from pediatricians (31.1% of whom were at critical medicine departments) and the remainder from specialists. The number of diagnosed patients has increased to 1 per 43.9 patients studied. Amino acid defects have been the most prevalent, the proportion of organic acid and carbohydrate disorders having increased in the last 10 years, associated with improved diagnostic facilities. The most frequently diagnosed diseases were PKU, type 1a glycogen storage, and maple syrup urine disease (MSUD), their frequency apparently varying among different regions of Mexico. Other results of our program include training of specialists and technicians, development of the Latin American Metabolic Information Network, a procedure to locally prepare a special food product low in phenylalanine for the treatment of PKU patients, and extension of approaches for these disorders to the investigation metabolic derangements of infant malnutrition. This work demonstrates that inherited metabolic diseases constitute a significant load in pediatric pathology and that their study can and should be pursued in developing nations.

[Characteristics of prostatic cancer undetected in the first assessment of a screening program. Quality control]. / Características de los cánceres de próstata no detectados en la primera evaluación de un programa de screening. Un control de calidad.

OBJECTIVE: To study the results of the second round in the subjects with negative tests in the first round of a prostate cancer screening program and to analyze the characteristics of the tumors that were not detected in the first round. METHODS: Of 5188 males evaluated in a prostate cancer screening program, 976 with negative tests in the first round (804 with PSA < or = 4 ng/ml; 172 with PSA > 4 ng/ml and a negative biopsy) accepted to undergo subsequent tests. During the second round, 163 biopsies were indicated. The biopsy results and the characteristics of the tumors detected were analyzed. RESULTS: The biopsy yield was higher (but not significantly) in the first round (80 cancers/481 biopsies; 16.6%) than in the second round (13 cancers/115 biopsies; 11.3%). Of the 163 biopsies indicated in the second round, 115 were performed and 13 cancers were detected (10 of these patients had a high PSA in the first round). The univariate analysis showed no differences for age, PSA, PSA density, prostate volume, transrectal US findings, or Gleason score in the cases diagnosed in the first round and those detected in the second round. However, there was a higher proportion of tumors with abnormal DRE in the cancers detected in the first round than in the second round, (31.3% vs 7.7%, respectively; p = 0.02). There was a higher proportion of tumors clinically detected in the second round than in the first round (100% vs 75%, respectively; p = 0.043). The multivariate analysis only showed differences for the DRE findings (p = 0.045). CONCLUSION: A significant number of tumors are undetected in prostate cancer screening programs. Although the biopsy yield may be slightly lower in subsequent rounds, there is a strong trend of detecting more localized tumors (and therefore potentially curable). We have found no correlation between a greater prostate volume and tumors that were undetected in the first round.

[Value of Markovian nuclear texture to predict progression in surface transitional cell carcinoma of the bladder]. / Utilidad de las texturas nucleares Markovianas en la predicción de la progresión en los CCT superficiales de vejiga.

The aim of this work has been to determine if the DNA and nuclear Markovian textures of tissue sections evaluated by image cytometry correlate with the histologic grade and the progression probability of superficial transitional carcinoma of the bladder. In our study, DNA ploidy is related to histologic grade in that aneuploidy frequency increases with a higher grade of malignancy. Image analyses of superficial TCC tissue sections of the bladder, has allowed us to identify "sub-visual parameters" as well as nuclear textures that according to our results can be useful in clarifying the evolutive behaviour of these tumours. Two Markovian textures that identify entropy (TXI) and mean internal contrast (TXB) allow to discriminate between histologic grades as well as progression or non-progression. In conclusion, image analysis cytometry of paraffin embedded tissue sections of TCC of the bladder supplies densitometric parameters related to grade and provides valuable information for the prediction of progression. Quantification of chromatin pattern description in Feulgen-stained nuclei using the Markovian method can be useful in this context.